Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
221 stopped studies mapped to Malignant Skin Neoplasm and descendants · 91% state a reason
Over the 221 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | Phase 1 | terminated | Mar 9, 2020 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT05436990 | Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal… | Phase 2 | terminated | Jun 29, 2022 | Yonsei University | According to the protocol criteria, during the Phase 1 analysis, the registered participants'… | Other (stated, no rule matched) |
| NCT00866684 | Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based…(PROSKIN) | Phase 4 | terminated | Mar 20, 2009 | Charite University, Berlin, Germany | Insufficient patient recruitment | Enrollment / accrual |
| NCT05576077 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors(STARLING) | Phase 1 | terminated | Oct 12, 2022 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT04502888 | Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell… | Phase 1 | terminated | Aug 6, 2020 | Shattuck Labs, Inc. | Sponsor decision | Sponsor / business decision |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | Phase 1 | terminated | Feb 5, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04807777 | Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous… | Phase 2 | terminated | Mar 19, 2021 | Columbia University | Departure of the original investigator | Investigator |
| NCT04375527 | Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or… | Phase 2 | terminated | May 5, 2020 | Jonsson Comprehensive Cancer Center | poor enrollment | Enrollment / accrual |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT06207786 | Nasal Iodine Swab Versus Oral Antibiotic to Prevent Surgical Site Infection After… | N/A | withdrawn | Jan 17, 2024 | Mayo Clinic | Lack of resources to support the trial | Other (stated, no rule matched) |
| NCT02097225 | Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or… | Phase 1 | terminated | Mar 27, 2014 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT06638736 | A Randomized Controlled Trial Comparing Sutures vs Staples for High Tension Closures | N/A | withdrawn | Oct 15, 2024 | University of Kansas Medical Center | Administrative withdrawal, study was never approved by IRB | Other (stated, no rule matched) |
| NCT05200143 | Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma | Phase 2 | terminated | Jan 20, 2022 | Providence Health & Services | Withdrawn support from BMS. | Other (stated, no rule matched) |
| NCT03370861 | How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes(MINING) | — | terminated | Dec 12, 2017 | Washington University School of Medicine | Subject recruitment was limited severely by the 2020-2023 COVID-19 pandemic, which led this study… | COVID-19 / pandemic |
| NCT04676087 | Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or… | Phase 1 / Phase 2 | terminated | Dec 19, 2020 | Emory University | Lack of funding | Funding |
| NCT03327064 | A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for… | Phase 1 / Phase 2 | withdrawn | Oct 31, 2017 | University of Alabama at Birmingham | COVID-19 pandemic, unable to enroll participants | COVID-19 / pandemic |
| NCT06384820 | Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental… | Phase 2 | withdrawn | Apr 25, 2024 | Regeneron Pharmaceuticals | Business Decision | Sponsor / business decision |
| NCT06084845 | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy… | Phase 2 | withdrawn | Oct 16, 2023 | ECOG-ACRIN Cancer Research Group | A phase III trial of the investigational agent failed to pass futility boundaries at interim… | Efficacy / futility |
| NCT03789864 | Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis…(BDI) | N/A | terminated | Dec 31, 2018 | Indiana University | Lack of accrual in a timely fashion | Enrollment / accrual |
| NCT05050006 | ITIL-168 in Advanced Melanoma(DELTA-1) | Phase 2 | terminated | Sep 20, 2021 | Instil Bio | Business Decision | Sponsor / business decision |
| NCT05412875 | Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung | N/A | withdrawn | Jun 9, 2022 | Ohio State University Comprehensive Cancer Center | Funding lapse | Funding |
| NCT05643755 | Preoperative Image-based Education Effect on Postoperative Satisfaction of Patients… | N/A | withdrawn | Dec 9, 2022 | Johns Hopkins University | Lack of personnel to complete study. | Other (stated, no rule matched) |
| NCT02978443 | A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab… | Phase 2 | terminated | Dec 1, 2016 | Georgetown University | Lack of Enrollment | Enrollment / accrual |
| NCT03727789 | CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma | Phase 1 | terminated | Nov 1, 2018 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT04410874 | Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer(MUSIC-01) | Phase 1 / Phase 2 | terminated | Jun 1, 2020 | Ivan Litvinov | Inability to recruit patients/lack of funding | Enrollment / accrual |
| NCT04337931 | A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic… | Phase 2 | terminated | Apr 8, 2020 | Apexigen America, Inc. | Business decision (not due to safety reason). | Safety / toxicity |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | Phase 1 | terminated | Jan 16, 2013 | Stanford University | Planned Future Study | Other (stated, no rule matched) |
| NCT05482074 | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | Phase 2 | withdrawn | Aug 1, 2022 | Dana-Farber Cancer Institute | Principal Investigator left the institute | Investigator |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Phase 1 | terminated | Jan 28, 2020 | Atreca, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT05138458 | A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL(IMAGINE) | Phase 1 / Phase 2 | suspended | Dec 1, 2021 | Myeloid Therapeutics | Temporary operational pause; no safety concerns. | Safety / toxicity |
| NCT04795869 | Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral… | Phase 2 | withdrawn | Mar 12, 2021 | Northwestern University | Study inactivated due to zero accruals | Enrollment / accrual |
| NCT04176900 | 3D Printed Rigid Bolus Versus Silicone Bolus for Treatment of Tumors Involving the Skin:… | N/A | withdrawn | Nov 25, 2019 | Nova Scotia Cancer Centre | Closed during Covid Pandemic, and no longer supported locally | COVID-19 / pandemic |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant… | Phase 2 | terminated | Jan 8, 2010 | University of Nebraska | Study was closed to accrual for safety related to the frequency of BK infections. | Safety / toxicity |
| NCT05729139 | Cemiplimab/Peg-Interferon-α in Advanced CSCC | Phase 1 | withdrawn | Feb 15, 2023 | Baptist Health South Florida | PI is leaving institution prior to study opening for accrual. | Enrollment / accrual |
| NCT02748564 | Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | Phase 2 | terminated | Apr 22, 2016 | Rutgers, The State University of New Jersey | Study Complete | Other (stated, no rule matched) |
| NCT04252612 | Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A… | Early Phase 1 | withdrawn | Feb 5, 2020 | H. Lee Moffitt Cancer Center and Research Institute | Poor accrual | Enrollment / accrual |
| NCT04348916 | Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With… | Phase 1 | terminated | Apr 16, 2020 | Oncorus, Inc. | Terminated due to Oncorus portfolio reprioritization | Sponsor / business decision |
| NCT01579318 | Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma(CTCL) | Phase 2 | terminated | Apr 17, 2012 | OncoSec Medical Incorporated | Due to company resource constraints | Sponsor / business decision |
| NCT02036476 | Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma | Phase 2 | terminated | Jan 15, 2014 | Dana-Farber Cancer Institute | Lack of accrual. | Enrollment / accrual |
| NCT05220748 | RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients… | Phase 1 | withdrawn | Feb 2, 2022 | Rakuten Medical, Inc. | Decision was made due to a strategic re-evaluation of pipelines; no patients were enrolled. | Enrollment / accrual |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory… | Phase 1 | terminated | Sep 7, 2016 | Pfizer | not stated | Not stated |
| NCT03630601 | Photoacoustic Imaging in Diagnosing Changes in Tumors in Participants With Breast Cancer,… | N/A | terminated | Aug 15, 2018 | Roswell Park Cancer Institute | Diagnostic issues | Other (stated, no rule matched) |
| NCT04611321 | Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma | Phase 1 / Phase 2 | terminated | Nov 2, 2020 | Innovent Biologics (Suzhou) Co. Ltd. | Due to the company's development strategy adjustment, Innovent Biologics has decided not to… | Sponsor / business decision |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | Phase 1 | terminated | Aug 2, 2019 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT02314247 | Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell… | Phase 2 | terminated | Dec 11, 2014 | Karyopharm Therapeutics Inc | Due to enrollment challenges | Enrollment / accrual |
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | Phase 1 / Phase 2 | terminated | Feb 2, 2022 | Rubius Therapeutics | The Sponsor terminated study after dosing 2 dose groups (7 pts) and closed trial on 11/30/22.… | Other (stated, no rule matched) |
| NCT05572463 | A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated… | Phase 1 / Phase 2 | withdrawn | Oct 7, 2022 | Innovent Biologics (Suzhou) Co. Ltd. | Sponsor Strategy | Sponsor / business decision |
| NCT04242173 | Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC | Phase 2 | terminated | Jan 27, 2020 | H. Lee Moffitt Cancer Center and Research Institute | Lack of Interest | Other (stated, no rule matched) |
| NCT03921073 | Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma | Phase 2 | terminated | Apr 19, 2019 | H. Lee Moffitt Cancer Center and Research Institute | Sponsor Terminated Funding | Funding |
| NCT02811783 | Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of… | Phase 3 | terminated | Jun 23, 2016 | Elorac, Inc. | Sponsor decision | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Apr 23, 2025source: clinicaltrials